Skip to product information
L-Arginine 8 g
L-Arginine 8 g

L-Arginine 8 g

Incl. VAT

Prescription

Presentation: 50 ml infusion concentrate

Composition: L-arginine HCl, citrate-phosphate buffer, water for injection

Prescription status: prescription only

Storage: does not require refrigeration

Shelf life: 1 year after manufacture

After completing your order, you will receive a link through which you can securely upload your prescription.
Anmeldung erforderlich
Jetzt einloggen Jetzt registrieren
PRODUCT INFORMATION

Composition:

  • L-arginine HCl 8000 mg 
  • Citric acid-phosphate buffer 
  • Water for injection to 50 ml 

Administration: i.v., always prepare the infusion solution freshly dilute in 250 ml of 0.9% NaCl in hypotensive patients 500 ml, see side effects

Infusion set: Intrafix © Air P 

Infusion duration: 30-45 minutes 

Therapy interval: 1x per week, based on the patient's health status 

Duration of treatment: 6 weeks, based on the patient's health status 

Storage: 15 – 25°C  

Shelf life: 1 year after manufacture

Side effects: A high L-arginine level can favor the reactivation of herpes simplex viruses in the presence of low L-lysine supply. Due to increased NO formation under L-arginine, platelet aggregation can be inhibited, which potentially leads to a slight prolongation of the bleeding time. Existing hypotension can be exacerbated. Therefore, blood pressure measurement is recommended before infusion and the volume of the carrier solution should be increased to 500 ml. 
THERAPY RECOMMENDATION

Positive Effects:

  • L-Arginine is a semi-essential amino acid, but many studies show L-Arginine to be indispensable. L-Arginine serves as a protein building block.
  • L-Arginine is the only precursor of endothelial nitric oxide synthase (eNOS). NO production causes vasodilation.
  • L-Arginine induces iNOS in immune system cells. Here, NO has a cytotoxic effect and serves to defend against bacteria.
  • L-Arginine is the precursor of neuronal NOS (nNOS) and induces the secretion of glutamate.
  • L-Arginine activates mitochondrial NOS.
  • L-Arginine, as a precursor of nitric oxide (NO), has a dichotomous effect on cancer cells. NO is associated with the pathogenesis of various types of tumors. It acts either as an enhancer or as an inhibitor of cancer development.
  • L-Arginine is a precursor of creatine, ornithine, and citrulline.
  • Creatine is composed of L-arginine, L-methionine, and glycine.

Therapy recommendations: There is evidence that the properties of the substances contained in the product can have a positive effect on health disorders of the mentioned indications:

  • in cases of NO deficiency, L-arginine deficiency
  • in cases of vasoconstriction, vascular diseases, and circulatory disorders (arteriosclerosis, sudden hearing loss); NO promotes blood circulation and reduces platelet aggregation
  • in cases of elevated ADMA plasma levels and endothelial dysfunctions
  • in cases of high blood pressure
  • in cases of type 2 diabetes mellitus and insulin resistance; L-arginine promotes insulin release; glycogen synthesis
  • in cases of acute and chronic infections by stimulating T-lymphocyte formation, boosts TH1 response
  • in pain therapy by increasing the body's own pain-relieving
  • peptide Kyotorphin (Tyrosinyl-arginine), analgesic
  • Sport: anabolic effect, increased secretion of STH, and increased fat breakdown (lipolysis)
  • improved wound healing in injuries and burns
  • for the treatment of erectile dysfunction
  • in neurodegeneration: Ammonia breakdown in the urea cycle is promoted

Contraindications:Do not use in children under 6 years of age. In cases of impaired kidney, liver, or heart function and albumin deficiency, an adjustment of the individual dose is recommended. Patients taking beta-blockers have an increased risk of decompensated cardiovascular reaction, as beta-blockers inhibit the effect of adrenaline (emergency medical treatment). Patients with a tendency to allergic reactions and/or diseases based on histamine release (e.g., asthma) should be asked about known allergens in accordance with the principles of therapeutic due diligence.

Contraindications:pathologically increased iNO concentrations, which cause an increase in oxidative and nitrosative cell stress.

Note for doctors and therapists: Generally, for individual prescriptions, the doctor/therapist determines the indication. The suggestion is merely a recommendation for a therapy option, with the dosage and frequency of application being solely at the discretion of the doctor/therapist. The treating therapist is responsible for the treatment and must individually review and assess the respective application for each patient before starting treatment.
Shipping Information

NATIONAL:

  • Standard shipping: €9.95 incl. VAT
  • Free shipping on orders over €200.00 (does not apply to refrigerated goods and express shipments)
  • Refrigerated and express shipping: €25.95 incl. VAT

Note: If individual products are unavailable, partial deliveries may occur, incurring no additional shipping costs.
Any requested partial deliveries will be charged.

WITHIN THE EU:
For shipments to countries in EU Zone 1, we charge logistics costs of €75.00 (incl. VAT).

For shipments to countries in EU Zone 2, we charge logistics costs of €105.00 (incl. VAT).

THIRD COUNTRIES:
The customer is asked to inquire about the logistics costs incurred for the respective country.
References

We have researched the literature references with the greatest possible care. Nevertheless, we assume no liability for the completeness and up-to-date nature of the study information. Many of the therapy options mentioned in the product information are based on findings obtained from animal or human cell cultures, animal experiments, observational studies, and, to a lesser extent, randomized controlled trials (RCTs).
The study situation regarding complementary medicines is subject to continuous development, which can sometimes lead to different results. We therefore recommend that therapists always carefully check the current study situation before using such preparations.

1) Gröber, U. 2008. Orthomolecular Medicine. A Guide for Pharmacists and Doctors

2) Gröber, U. 2010. Micronutrients – Metabolic Tuning – Prevention – Therapy. Scientific Publishing Company

3) Böhm U, Muss C, Pfisterer M. Rational Diagnostics in Orthomolecular Medicine – Optimal Therapy through Individual Diagnostics. Hippokrates, 2004

4) Burgerstein, L. 2023. Handbook of Nutrients

5) Stossier H, Stossier G. Practical Handbook of Orthomolecular Medicine. Ärzteverlag, 2023

6) Schmidt N, Schimdt E. Micronutrient Therapy. Urban & Fischer Verlag, 2022

7) Schmidbauer C, Hofstätter G. Micronutrient Coach – The Great BIOGENA Compendium of Nutrients. Ärzteverlag, 201

8) Guoyao Wu, Cynthia J Meininger, Catherine J McNeal, Fuller W Bazer, J Marc Rhoads, Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans, Adv Exp Med Biol., 2021, 1332:167-187

9) A J Maxwell, J P Cooke, Cardiovascular effects of L-arginine, Curr Opin Nephrol Hypertens, 1998, 7(1):63-70

10) Alexander Ströhle, Helene von Bibra, Andreas Hahn, L-Arginine and vascular health, Med Monatsschr Pharm., 2016, 39(12):515-20

11) Kylie M Venardos, Niwanthi W Rajapakse, David Williams, Louise S Hoe, Jason N Peart, David M Kaye, Cardio-protective effects of combined l-arginine and insulin: Mechanism and therapeutic actions in myocardial ischemia-reperfusion injury, Eur J Pharmacol, 2015, 769:64-70

12) D Menafra, C de Angelis, F Garifalos, M Mazzella, G Galdiero, M Piscopo, M Castoro, N Verde, C Pivonello, C Simeoli, R S Auriemma, A Colao, R Pivonello, Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial, J Endocrinol Invest., 2022, 45(5):941-961

13) Jill A Kanaley, Growth hormone, arginine and exercise, Curr Opin Clin Nutr Metab Care., 2008, 11(1):50-4

14) Anissa Feby Canintika, Ismail Hadisoebroto Dilogo, Guntur Utama Putera, Muhammad Yafidy, Oral L-arginine supplementation for fracture healing: a systematic review of preclinical studies, Acta Orthop Belg., 2022, 88(3):609-615

15) Sahar Cheshmeh, Niloofar Hojati, Arman Mohammadi, Negin Rahmani, Shima Moradi, Yahya Pasdar, Negin Elahi, The use of oral and enteral tube-fed arginine supplementation in pressure injury care: A systematic review and meta-analysis, Nurs Open, 2022, 9(6):2552-2561

16) H Takagi, Physiological and pharmacological actions of a neuroactive dipeptide, kyotorphin, and its precursor, L-arginine, and clinical application, Nihon Yakurigaku Zasshi., 1990, 96(3):85-96